Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort.
作者信息
Gillis Nancy K, Hicks J Kevin, Bell Gillian C, Daly Ashley J, Kanetsky Peter A, McLeod Howard L
机构信息
Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; Center for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA; DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
出版信息
J Invest Dermatol. 2017 Sep;137(9):2021-2023. doi: 10.1016/j.jid.2017.05.010. Epub 2017 May 23.
Abstract
摘要
相似文献
1
Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort.
J Invest Dermatol. 2017 Sep;137(9):2021-2023. doi: 10.1016/j.jid.2017.05.010. Epub 2017 May 23.
2
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention.
Am J Med. 2016 Nov;129(11):1221-1225. doi: 10.1016/j.amjmed.2016.03.022. Epub 2016 Apr 15.
3
Stevens-Johnson syndrome and toxic epidermal necrolysis at the University Hospital of the West Indies, Jamaica.
West Indian Med J. 2013 Sep;62(7):589-92. doi: 10.7727/wimj.2013.031.
4
Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system.
Int J Clin Pract. 2021 Aug;75(8):e14273. doi: 10.1111/ijcp.14273. Epub 2021 May 17.
5
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.
Drug Saf. 2019 Jan;42(1):55-66. doi: 10.1007/s40264-018-0711-x.
6
Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Pediatrics. 2009 Feb;123(2):e297-304. doi: 10.1542/peds.2008-1923. Epub 2009 Jan 19.
7
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.
Arch Dermatol. 2002 Aug;138(8):1019-24. doi: 10.1001/archderm.138.8.1019.
8
Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
Drug Saf. 2005;28(10):917-24. doi: 10.2165/00002018-200528100-00008.
9
Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with anticonvulsants in a Japanese population: Matched case-control and cohort studies.
Allergol Int. 2021 Jul;70(3):335-342. doi: 10.1016/j.alit.2021.01.004. Epub 2021 Feb 19.
10
Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis in adults.
Int J Dermatol. 2017 Apr;56(4):e78-e79. doi: 10.1111/ijd.13125. Epub 2016 Nov 21.
引用本文的文献
1
Fatal Case of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Induced by Doxycycline or Flucloxacillin in a 77-Year-Old Woman: A Rare but Serious Adverse Drug Reaction.
Cureus. 2025 Jul 2;17(7):e87202. doi: 10.7759/cureus.87202. eCollection 2025 Jul.
2
Immune Checkpoint Inhibitors as Independent and Synergistic Drivers of SJS/TEN: A FAERS-Based Analysis.
medRxiv. 2025 Jun 30:2025.06.21.25330030. doi: 10.1101/2025.06.21.25330030.
3
Accelerated Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome in Response to TMP-SMX: A Case Report.
Am J Case Rep. 2025 Jun 13;26:e948217. doi: 10.12659/AJCR.948217.
4
A nationwide study of Stevens-Johnson syndrome and toxic epidermal necrolysis in hospitalized pregnant women in the United States, 2009-2020.
JAAD Int. 2024 Apr 9;16:175-182. doi: 10.1016/j.jdin.2024.04.002. eCollection 2024 Sep.
5
Ophthalmic Aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Narrative Review.
Ophthalmol Ther. 2023 Aug;12(4):1795-1811. doi: 10.1007/s40123-023-00725-w. Epub 2023 May 4.
6
Metagenomics and chemotherapy-induced nausea: A roadmap for future research.
Cancer. 2022 Feb 1;128(3):461-470. doi: 10.1002/cncr.33892. Epub 2021 Oct 13.
7
A Case of Stevens-Johnson Syndrome in Recurrent Late-Stage Ovarian Cancer Patient after Management of Chronic Pain with Elastomeric Pump.
Curr Oncol. 2021 Aug 3;28(4):2928-2932. doi: 10.3390/curroncol28040256.
8
Fatal pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis: Three case reports.
Medicine (Baltimore). 2020 Mar;99(12):e19431. doi: 10.1097/MD.0000000000019431.
9
Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer.
J Am Acad Dermatol. 2021 Feb;84(2):273-282. doi: 10.1016/j.jaad.2020.03.010. Epub 2020 Mar 12.
10
Ribociclib-Related Stevens-Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review.
J Breast Cancer. 2019 Dec;22(4):661-666. doi: 10.4048/jbc.2019.22.e44.
本文引用的文献
1
The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK.
J Invest Dermatol. 2017 Jun;137(6):1240-1247. doi: 10.1016/j.jid.2017.01.031. Epub 2017 Feb 12.
2
Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies.
Br J Dermatol. 2015 Nov;173(5):1224-31. doi: 10.1111/bjd.14052. Epub 2015 Oct 19.
3
Extensive toxic epidermal necrolysis versus acute graft versus host disease after allogenic hematopoietic stem-cell transplantation: challenges in diagnosis and management.
J Burn Care Res. 2014 Nov-Dec;35(6):e431-5. doi: 10.1097/BCR.0000000000000040.
4
Life-threatening dermatologic adverse events in oncology.
Anticancer Drugs. 2014 Feb;25(2):225-34. doi: 10.1097/CAD.0000000000000032.
5
Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study.
Am J Clin Dermatol. 2012 Feb 1;13(1):49-54. doi: 10.2165/11593240-000000000-00000.
6
Toxic epidermal necrolysis and Steven-Johnson syndrome in oncologic patients.
Eur Rev Med Pharmacol Sci. 2007 Jul-Aug;11(4):269-74.
7
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.
J Invest Dermatol. 2008 Jan;128(1):35-44. doi: 10.1038/sj.jid.5701033. Epub 2007 Sep 6.
8
Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry.
J Clin Epidemiol. 1996 Jul;49(7):769-73. doi: 10.1016/0895-4356(96)00035-2.
9
Using a claims database to investigate drug-induced Stevens-Johnson syndrome.
Stat Med. 1991 Apr;10(4):565-76. doi: 10.1002/sim.4780100408.
10
Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany.
Arch Dermatol. 1991 Jun;127(6):839-42. doi: 10.1001/archderm.1991.01680050083008.
Zotero 插件